Tag Archives: enterosorbents

Inclusion of enterosorbents in anti-inflammatory therapy improve treatment effectiveness in copd patients during exacerbations

S. V. Kucher*, O. V. Lototska

I. Horbachevsky Ternopil National Medical University, Ternopil, Ukraine;
*e-mail: kuchersv@tdmu.edu.ua

Received: 29 January 2021; Accepted: 23 April 2021

Inflammation plays a key role in the development of chronic obstructive pulmonary disease (COPD), and manifests as increased levels of inflammation markers such as cytokines. The purpose of this study was to examine the effect of enterosorbents on IL-1β, TNF-α and IL-10 levels in COPD patients with exacerbations, while taking into account their ages. Patients were divided into two age groups: age group 1 (40-59 years) and age group 2 (>60 years). Levels of IL-1β, TNF-α and IL-10 were determined by enzyme-linked immunosorbent assay. Levels of pro-inflammatory and anti-inflammatory cytokines were increased in both age groups of COPD patients during exacerbations compared to the healthy control group. Pro-inflammatory cytokines (IL-1β, TNF-α) increased more in age group 2. Basic therapy (BT) had positive impacts. Addition to BT of the enterosorbents Enterosgel and Carboline decreased serum levels of IL-1β, TNF-α and IL-10 in both age groups more than after BT alone. Greater changes were observed in age group 2. We found that addition of the enterosorbents Carboline or Enterosgel to basic therapy of COPD patients during exacerbations decreased levels of IL-1β, TNF-α and IL-10 in patients of both age groups (40-59 years and >60 years).